Daisy Huynh

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4613858/publications.pdf Version: 2024-02-01



Πλιςν Ημγνιμ

#	Article	IF	CITATIONS
1	Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant. Nature Communications, 2020, 11, 2996.	12.8	98
2	Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma. Nature Cancer, 2020, 1, 493-506.	13.2	209
3	Antibody-Dependent Cellular Phagocytosis by Macrophages is a Novel Mechanism of Action of Elotuzumab. Molecular Cancer Therapeutics, 2018, 17, 1454-1463.	4.1	70
4	Platelets Enhance Multiple Myeloma Progression via IL-1β Upregulation. Clinical Cancer Research, 2018, 24, 2430-2439.	7.0	44
5	Profiling of circulating exosomal miRNAs in patients with Waldenström Macroglobulinemia. PLoS ONE, 2018, 13, e0204589.	2.5	17
6	Bortezomib overcomes the negative impact of CXCR4 mutations on survival of Waldenstrom macroglobulinemia patients. Blood, 2018, 132, 2608-2612.	1.4	29
7	Safety and immunogenicity of conjugate quadrivalent meningococcal vaccination after hematopoietic cell transplantation. Blood Advances, 2018, 2, 1272-1276.	5.2	9
8	Inhibition of microRNA-138 enhances bone formation in multiple myeloma bone marrow niche. Leukemia, 2018, 32, 1739-1750.	7.2	34
9	Blocking IFNAR1 inhibits multiple myeloma–driven Treg expansion and immunosuppression. Journal of Clinical Investigation, 2018, 128, 2487-2499.	8.2	80
10	The Role of Clonal Hematopoiesis of Indeterminate Potential (CHIP) in Multiple Myeloma: Immunomodulator Maintenance Post Autologous Stem Cell Transplant (ASCT) Predicts Better Outcome. Blood, 2018, 132, 749-749.	1.4	6
11	Single-Cell RNA Sequencing Reveals Compromised Immune Microenvironment in Precursor Stages of Multiple Myeloma. Blood, 2018, 132, 2603-2603.	1.4	1
12	Deciphering Clonal Evolution and Dissemination of Multiple Myeloma Cells In Vivo. Blood, 2018, 132, 55-55.	1.4	0
13	Dissecting the Epigenetic Landscape of Smoldering, Newly Diagnosed and Relapsed Multiple Myeloma Revealed IRAK3 As a Marker of Disease Progression. Blood, 2018, 132, 3896-3896.	1.4	1
14	Prognostic role of circulating exosomal miRNAs in multiple myeloma. Blood, 2017, 129, 2429-2436.	1.4	214
15	A novel in vivo model for studying conditional dual loss of BLIMPâ€1 and p53 in Bâ€cells, leading to tumor transformation. American Journal of Hematology, 2017, 92, E138-E145.	4.1	3
16	Inhibiting the oncogenic translation program is an effective therapeutic strategy in multiple myeloma. Science Translational Medicine, 2017, 9, .	12.4	53
17	The Mutational Landscape of Circulating Tumor Cells in Multiple Myeloma. Cell Reports, 2017, 19, 218-224.	6.4	92
18	In Vivo Genome-Wide Crispr Library Screen in a Xenograft Mouse Model of Tumor Growth and Metastasis of Multiple Myeloma. Blood, 2016, 128, 1137-1137.	1.4	2

DAISY HUYNH

#	Article	IF	CITATIONS
19	Whole-Exome Sequencing and Targeted Deep Sequencing of cfDNA Enables a Comprehensive Mutational Profiling of Multiple Myeloma. Blood, 2016, 128, 197-197.	1.4	8
20	Whole Exome Sequencing and Targeted Sequencing Reveal the Heterogeneity of Genomic Evolution and Mutational Profile in Smoldering Multiple Myeloma. Blood, 2016, 128, 237-237.	1.4	0
21	Microrna-138 Regulates Osteogenic Differentiation and Its Inhibition Presents a Novel Therapeutic Line to Prevent Bone Lytic Lesions in Multiple Myeloma. Blood, 2016, 128, 4483-4483.	1.4	Ο
22	CXCR4 Regulates Extra-Medullary Myeloma through Epithelial-Mesenchymal-Transition-like Transcriptional Activation. Cell Reports, 2015, 12, 622-635.	6.4	123
23	The cancer glycome: Carbohydrates as mediators of metastasis. Blood Reviews, 2015, 29, 269-279.	5.7	91
24	Mutational Profile and Prognostic Relevance of Circulating Tumor Cells in Multiple Myeloma. Blood, 2015, 126, 23-23.	1.4	37
25	Characterization of the Role of Regulatory T Cells (Tregs) in Inducing Progression of Multiple Myeloma. Blood, 2015, 126, 502-502.	1.4	4
26	MYC Regulation Via the LIN28B/Let-7 Axis in Multiple Myeloma. Blood, 2015, 126, 1755-1755.	1.4	0
27	Circulating Exosomal microRNAs Are Prognostic Markers in Multiple Myeloma. Blood, 2015, 126, 1770-1770.	1.4	4
28	Platelets/Megakaryocytes Are Critical Regulators of Tumor Progression in Multiple Myeloma. Blood, 2015, 126, 1793-1793.	1.4	1
29	Regulation of microRNAs in cancer metastasis. Biochimica Et Biophysica Acta: Reviews on Cancer, 2014, 1845, 255-265.	7.4	132
30	Pyk2 promotes tumor progression in multiple myeloma. Blood, 2014, 124, 2675-2686.	1.4	51
31	Novel CXCR4-Targeted Therapy to Inhibit Multiple Myeloma Bone Dissemination. Blood, 2014, 124, 4709-4709.	1.4	1
32	Prognostic Value of Circulating Exosomal microRNAs in 112 Patients with Multiple Myeloma. Blood, 2014, 124, 2056-2056.	1.4	0
33	Metabolomic Profiling Identifies Mechanisms Regulating Hypoxia-Induced Drug Resistance In Multiple Myeloma. Blood, 2013, 122, 121-121.	1.4	0